Expression of ζ in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 6, 2002, Pages 631-640

  Kuss, Iris ^d   Rabinowich, Hannah ^a,d   Gooding, William ^b,d   Edwards, Robert ^c,d   Whiteside, Theresa L ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

IL 2 therapy; Ovarian carcinoma; Response to IL 2 therapy; T cell signaling; chain

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; RECOMBINANT INTERLEUKIN 2;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FLOW CYTOMETRY; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 12244261579     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802320970235     Document Type: Article

References (36)

1. Lai P, Rabinowich H., Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 1996;2:161-173.
2. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M, Edwards R, Whiteside TL. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996;68:276-284.
3. Rabinowich H, Reichert TE, Kashii Y, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: Implications for altered expression of TcR in tumor-associated lymphocytes. J Clin Invest 1998;101:2579-2588.
4. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Caspase-mediated degradation of TcRζ chain. Cancer Res 1999;59:1422-1427.
5. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent of low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998;58:5344-5347.
6. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Iwashige H, Aridome K, Hokita S, Aikou T. CD3-ζ chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 2002;94:1437-1442.
7. Lotze MT, Rosenberg SA. Interleukin-2: Clinical applications, in De Vita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy with Interleukin-2 (1995); Philadelphia, Lippincott, pp 207-253.
8. Wojtowicz-Praga S. Reversal of tumor induced immunosuppression: A new approach to cancer therapy. J Immunother 1997;20:165-167.
9. Rosenberg SA. Perspectives on the use of interleukin-2 in cancer. Cancer J Sci Am 1997;3:S2-6.
10. Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, Kowal CD, Kunschner AJ, Baldisseri M, Kirkwood JM, Herberman RB. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion. J Clin Oncol 1997;15:3399-3407.
11. Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, Snyderman C, Johnson JT, Myers E, Herberman RB, Rubin J, Kirkwood JM, Vlock DR. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 1993;3:53:5654-5662.
12. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-1798.
13. Zea AH, Brendan CD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, Ochoa AC. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995;1:1327-1335.
14. Healy CG, Simons JW, Carducci MA, Deweese TL, Bartkowski M, Tong KP, Bolton WE. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998;32:109-119.
15. Kolenko V, Wang Q, Riedy MC, Oshea J, Ritz J, Cathcart MK, Rayman P, Tubbs R, Edinger M, Novick A, Bukowski R, Finke J. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling. Role of soluble products from human renal cell carcinomas. J Immunol 1997;159:3057-3067.
16. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-5616.
17. Matsuda M, Petersson M, Lenke R, Taupin J-L, Magnusson I, Mellstedt H, Anderson P, Kiessling R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease. Int J Cancer 1995;61:765-772.
18. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL. Human immune cells in the tumor microenvironment: Mechanism responsible for signaling and functional defects. J Immunother 1998;21:295-306.
19. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996;2:1263-1272.
20. + peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001;7:947s-957s.
21. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61:4756-4760.
22. fγn, ZAP-70, and CD3ζ despite suppressed cytolytic activity. J Exp Med 1995;82:1029-1036.
23. Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC, Kiessling R. Primary chemically induced tumors induce profound immunosupression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res 1999;59:2950-2956.
24. Cardi G, Heaney JA, Schned AR, Phillips DM, Branda MT, Ernstoff MS. T-cell receptor ζ chain expression on tumor infiltrating lymphocytes from renal cell carcinoma. Cancer Res 1998;57:3517-3519.
25. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: A systematic review. Health Technol Assess 1998;2:1-84.
26. Kono K, Ressing ME, Brandt R.M.P, Melief CJM, Potkul RK, Andersson B, Petersson M, Kast WM, Kiessling R. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996;2:1825-1828.
27. Whiteside TI, Rabinowich H, The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 1998;46:175-184.
28. Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999;5:1263-1273.
29. Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 2000;6:1351-1364.
30. Hank JA, Sosman JA, Kohler PC, Bechhofer R, Storer B, Sondel PM. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lym phocytes from cancer patients following in vivo treatment with interleukin-2. J Biol Resp Mod 1990;9:5-14.
31. Kradin RL, Kurnick JT, Preffer FI, Dubinett SM, Dickersin GR, Pinto C. Adoptive immunotherapy with interleukin-2 results in the loss of delayed-type hypersensitivity responses and the development of immediate hypersensitivity to recall antigens. Clin Immunol Immunopath 1989;50:184-195.
32. Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer patients: Decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 1988;6:1440-1449.
33. Farace F, Angevin E, Vanderplancke J, Escudier B, Triebel F. The decreased expression of CD3 ζ chains in cancer patients is not reversed by IL-2 administration. Int J Cancer 1994;59:752-755.
34. Lenardo MJ. Interleukin-2 programs mouse α β T lymphocytes for apoptosis. Nature 1991;353:858-861.
35. Boehme SA, Lenardo MJ. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur J Immunol 1993;23:1552-1560.
36. Lotze MT. Future directions for recombinant interleukin-2 in cancer: A chronic inflammatory disorder. Cancer J Sci Am 1997;3:S106-108.